PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced publication of results from a non-randomized study of its Dermacyn® Wound Care (DWC) product, conducted in Italy for the treatment of wide post-surgical infected diabetic foot ulcers. The results were published in the current issue of International Journal of Lower Extremity Wounds and a reprint of the submission can be viewed online at: http://www.oculusis.com/europe/study.pdf.
